Characterization of blood pressure and endothelial function in TRPV4-deficient mice with L-NAME- and angiotensin II-induced hypertension

Yoshinori Nishijima, Xiaodong Zheng, Hayley Lund, Makoto Suzuki, David L. Mattson, David X. Zhang

Research output: Contribution to journalArticle

Abstract

Transient receptor potential vanilloid type 4 (TRPV4) is an endothelial Ca2+ entry channel contributing to endothelium-mediated dilation in conduit and resistance arteries. We investigated the role of TRPV4 in the regulation of blood pressure and endothelial function under hypertensive conditions. TRPV4-deficient (TRPV4-/-) and wild-type (WT) control mice were given L-NAME (0.5 g/L) in drinking water for 7 days or subcutaneously infused with angiotensin (Ang) II (600 ng/kg per minute) for 14 days, and blood pressure measured by radiotelemetry. TRPV4-/- mice had a lower baseline mean arterial pressure (MAP) (12-h daytime MAP, 94 ± 2 vs. 99 ± 2 mmHg in WT controls). L-NAME treatment induced a slightly greater increase in MAP in TRPV4-/- mice (day 7, 13 ± 4%) compared to WT controls (6 ± 2%), but Ang II-induced increases in MAP were similar in TRPV4-/- and WT mice (day 14, 53 ± 6% and 37 ± 11%, respectively, P < 0.05). Chronic infusion of WT mice with Ang II reduced both acetylcholine (ACh)-induced dilation (dilation to 10-5 mol/L ACh, 71 ± 5% vs. 92 ± 2% of controls) and the TRPV4 agonist GSK1016790A-induced dilation of small mesenteric arteries (10-8 mol/L GSK1016790A, 14 ± 5% vs. 77 ± 7% of controls). However, Ang II treatment did not affect ACh dilation in TRPV4-/- mice. Mechanistically, Ang II did not significantly alter either TRPV4 total protein expression in mesenteric arteries or TRPV4 agonist-induced Ca2+ response in mesenteric endothelial cells in situ. These results suggest that TRPV4 channels play a minor role in blood pressure regulation in L-NAMEbut not Ang II-induced hypertension, but may be importantly involved in Ang II-induced endothelial dysfunction.

Original languageEnglish (US)
Article numbere00199
JournalPhysiological reports
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

TRPV Cation Channels
NG-Nitroarginine Methyl Ester
Angiotensin II
Blood Pressure
Hypertension
Dilatation
Arterial Pressure
Acetylcholine
Mesenteric Arteries
Drinking Water
Endothelium

Keywords

  • Endothelium
  • Endothelium-derived hyperpolarizing factor
  • Hypertension
  • Mesenteric arteries
  • Nitric oxide
  • TRPV4

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Characterization of blood pressure and endothelial function in TRPV4-deficient mice with L-NAME- and angiotensin II-induced hypertension. / Nishijima, Yoshinori; Zheng, Xiaodong; Lund, Hayley; Suzuki, Makoto; Mattson, David L.; Zhang, David X.

In: Physiological reports, Vol. 2, No. 1, e00199, 01.01.2014.

Research output: Contribution to journalArticle

@article{a4a057be4d784b809776f45bb131e773,
title = "Characterization of blood pressure and endothelial function in TRPV4-deficient mice with L-NAME- and angiotensin II-induced hypertension",
abstract = "Transient receptor potential vanilloid type 4 (TRPV4) is an endothelial Ca2+ entry channel contributing to endothelium-mediated dilation in conduit and resistance arteries. We investigated the role of TRPV4 in the regulation of blood pressure and endothelial function under hypertensive conditions. TRPV4-deficient (TRPV4-/-) and wild-type (WT) control mice were given L-NAME (0.5 g/L) in drinking water for 7 days or subcutaneously infused with angiotensin (Ang) II (600 ng/kg per minute) for 14 days, and blood pressure measured by radiotelemetry. TRPV4-/- mice had a lower baseline mean arterial pressure (MAP) (12-h daytime MAP, 94 ± 2 vs. 99 ± 2 mmHg in WT controls). L-NAME treatment induced a slightly greater increase in MAP in TRPV4-/- mice (day 7, 13 ± 4{\%}) compared to WT controls (6 ± 2{\%}), but Ang II-induced increases in MAP were similar in TRPV4-/- and WT mice (day 14, 53 ± 6{\%} and 37 ± 11{\%}, respectively, P < 0.05). Chronic infusion of WT mice with Ang II reduced both acetylcholine (ACh)-induced dilation (dilation to 10-5 mol/L ACh, 71 ± 5{\%} vs. 92 ± 2{\%} of controls) and the TRPV4 agonist GSK1016790A-induced dilation of small mesenteric arteries (10-8 mol/L GSK1016790A, 14 ± 5{\%} vs. 77 ± 7{\%} of controls). However, Ang II treatment did not affect ACh dilation in TRPV4-/- mice. Mechanistically, Ang II did not significantly alter either TRPV4 total protein expression in mesenteric arteries or TRPV4 agonist-induced Ca2+ response in mesenteric endothelial cells in situ. These results suggest that TRPV4 channels play a minor role in blood pressure regulation in L-NAMEbut not Ang II-induced hypertension, but may be importantly involved in Ang II-induced endothelial dysfunction.",
keywords = "Endothelium, Endothelium-derived hyperpolarizing factor, Hypertension, Mesenteric arteries, Nitric oxide, TRPV4",
author = "Yoshinori Nishijima and Xiaodong Zheng and Hayley Lund and Makoto Suzuki and Mattson, {David L.} and Zhang, {David X.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/phy2.199",
language = "English (US)",
volume = "2",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Characterization of blood pressure and endothelial function in TRPV4-deficient mice with L-NAME- and angiotensin II-induced hypertension

AU - Nishijima, Yoshinori

AU - Zheng, Xiaodong

AU - Lund, Hayley

AU - Suzuki, Makoto

AU - Mattson, David L.

AU - Zhang, David X.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Transient receptor potential vanilloid type 4 (TRPV4) is an endothelial Ca2+ entry channel contributing to endothelium-mediated dilation in conduit and resistance arteries. We investigated the role of TRPV4 in the regulation of blood pressure and endothelial function under hypertensive conditions. TRPV4-deficient (TRPV4-/-) and wild-type (WT) control mice were given L-NAME (0.5 g/L) in drinking water for 7 days or subcutaneously infused with angiotensin (Ang) II (600 ng/kg per minute) for 14 days, and blood pressure measured by radiotelemetry. TRPV4-/- mice had a lower baseline mean arterial pressure (MAP) (12-h daytime MAP, 94 ± 2 vs. 99 ± 2 mmHg in WT controls). L-NAME treatment induced a slightly greater increase in MAP in TRPV4-/- mice (day 7, 13 ± 4%) compared to WT controls (6 ± 2%), but Ang II-induced increases in MAP were similar in TRPV4-/- and WT mice (day 14, 53 ± 6% and 37 ± 11%, respectively, P < 0.05). Chronic infusion of WT mice with Ang II reduced both acetylcholine (ACh)-induced dilation (dilation to 10-5 mol/L ACh, 71 ± 5% vs. 92 ± 2% of controls) and the TRPV4 agonist GSK1016790A-induced dilation of small mesenteric arteries (10-8 mol/L GSK1016790A, 14 ± 5% vs. 77 ± 7% of controls). However, Ang II treatment did not affect ACh dilation in TRPV4-/- mice. Mechanistically, Ang II did not significantly alter either TRPV4 total protein expression in mesenteric arteries or TRPV4 agonist-induced Ca2+ response in mesenteric endothelial cells in situ. These results suggest that TRPV4 channels play a minor role in blood pressure regulation in L-NAMEbut not Ang II-induced hypertension, but may be importantly involved in Ang II-induced endothelial dysfunction.

AB - Transient receptor potential vanilloid type 4 (TRPV4) is an endothelial Ca2+ entry channel contributing to endothelium-mediated dilation in conduit and resistance arteries. We investigated the role of TRPV4 in the regulation of blood pressure and endothelial function under hypertensive conditions. TRPV4-deficient (TRPV4-/-) and wild-type (WT) control mice were given L-NAME (0.5 g/L) in drinking water for 7 days or subcutaneously infused with angiotensin (Ang) II (600 ng/kg per minute) for 14 days, and blood pressure measured by radiotelemetry. TRPV4-/- mice had a lower baseline mean arterial pressure (MAP) (12-h daytime MAP, 94 ± 2 vs. 99 ± 2 mmHg in WT controls). L-NAME treatment induced a slightly greater increase in MAP in TRPV4-/- mice (day 7, 13 ± 4%) compared to WT controls (6 ± 2%), but Ang II-induced increases in MAP were similar in TRPV4-/- and WT mice (day 14, 53 ± 6% and 37 ± 11%, respectively, P < 0.05). Chronic infusion of WT mice with Ang II reduced both acetylcholine (ACh)-induced dilation (dilation to 10-5 mol/L ACh, 71 ± 5% vs. 92 ± 2% of controls) and the TRPV4 agonist GSK1016790A-induced dilation of small mesenteric arteries (10-8 mol/L GSK1016790A, 14 ± 5% vs. 77 ± 7% of controls). However, Ang II treatment did not affect ACh dilation in TRPV4-/- mice. Mechanistically, Ang II did not significantly alter either TRPV4 total protein expression in mesenteric arteries or TRPV4 agonist-induced Ca2+ response in mesenteric endothelial cells in situ. These results suggest that TRPV4 channels play a minor role in blood pressure regulation in L-NAMEbut not Ang II-induced hypertension, but may be importantly involved in Ang II-induced endothelial dysfunction.

KW - Endothelium

KW - Endothelium-derived hyperpolarizing factor

KW - Hypertension

KW - Mesenteric arteries

KW - Nitric oxide

KW - TRPV4

UR - http://www.scopus.com/inward/record.url?scp=85008930411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008930411&partnerID=8YFLogxK

U2 - 10.1002/phy2.199

DO - 10.1002/phy2.199

M3 - Article

AN - SCOPUS:85008930411

VL - 2

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 1

M1 - e00199

ER -